If the FDA Finalises the 503B Exclusion: What Happens to Your Compounded GLP-1

What was actually proposed

On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list — the register of active pharmaceutical ingredients that outsourcing facilities may lawfully compound from. The notice ran at 91 Fed. Reg. 23431.

Under section 503B, an outsourcing facility may generally compound from a bulk drug substance only if that substance appears on the bulks list, or if the compounded drug is on the FDA shortage list at the time of compounding. Neither condition currently holds for semaglutide or tirzepatide.

How both pathways closed

The shortage pathway went first, and less cleanly than most accounts suggest. FDA determined the tirzepatide injection shortage resolved on 2 October 2024. On 22 October that determination was remanded to the agency for reevaluation as part of litigation. On 5 March 2025 a district court denied the plaintiffs' preliminary injunction. Semaglutide followed in February 2025, with 22 May 2025 set as the end of enforcement discretion for outsourcing facilities.

Sources dating the tirzepatide resolution to December 2024 are describing the same contested sequence from a different point in it. Both dates appear in reputable coverage and neither is simply wrong.

Three things the proposal does not do

It is not a final rule. The agency considers submissions before making a determination, and has published no timeline.

It does not make compounded tirzepatide unlawful today. A proposal to exclude a substance from a list is not an enforcement action against anyone currently dispensing.

It does not address section 503A. Patient-specific compounding by state-licensed pharmacies operates under separate conditions. That distinction has become the most commercially consequential fact in this category.

Six things to do before a determination lands

1. Find out which pharmacy fills your prescription, and whether it is 503A or 503B. The proposal targets 503B bulk compounding. If your provider will not name the pharmacy, that is itself information.
2. Get your refund position in writing — specifically what happens to a prepaid balance if supply is interrupted for regulatory reasons. Twelve-month prepayments are common and this scenario is rarely addressed in published terms.
3. Price the approved alternatives now. Zepbound is $299 to $449 direct from LillyDirect. Both approved oral GLP-1s start at $149. Medicare's GLP-1 Bridge is $50 for eligible enrollees through 2027.
4. Ask your prescriber for a transition plan. What approved dose corresponds to where you are now.
5. Do not stockpile. Compounded sterile preparations carry beyond-use dates often shorter than an approved product's expiry.
6. Do not switch to an unapproved source. Research-peptide vendors are not a fallback — no prescriber, no pharmacy licence, no recourse.

What a switch would actually cost

Coverage changes the answer entirely. Establish it before comparing anything else.

For most people currently on compounded products, an approved alternative costs more per month — unless they have coverage, in which case it costs dramatically less. The comparison that matters is at a maintenance dose over a full year, not month one.

What a switch involves clinically

Compounded and approved products are not interchangeable by dose in any guaranteed way. Concentrations vary between compounders, and a compounded preparation has not been through bioequivalence testing — that is precisely what makes it not a generic.

Your prescriber makes a clinical judgement about the corresponding approved dose. The label's titration guidance applies: 2.5 mg for four weeks, then 5 mg, then increases no sooner than every four weeks based on tolerability and response.

The enforcement sequence behind the proposal

The bulks proposal is not an isolated action. Reading the sequence together makes the direction unambiguous.

More than 55 warning letters went to online sellers of compounded GLP-1s in September 2025. More than 40 followed to telehealth-based compounding pharmacies later that year. Thirty more were issued in early 2026 with an explicit threat of legal action without further notice, and a further 25 on 16 June 2026 alleging false or misleading website claims.

On 6 February 2026 the agency announced it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-approved compounded products. The bulks proposal followed twelve weeks later. Letters address individual actors one at a time; restricting the ingredient addresses the supply. That is a structural intervention rather than an enforcement one.

What the letters actually objected to

Mostly marketing, not manufacturing. The recurring allegation is that providers implied compounded GLP-1 products were equivalent to their FDA-approved counterparts.

That claim is false in a specific legal sense. An approved product has been through premarket review of safety, effectiveness and manufacturing quality. A generic has demonstrated bioequivalence and been approved on that basis, which is why it may be substituted. A compounded preparation has done neither. There is no generic tirzepatide or semaglutide, and a compounded preparation is not therapeutically equivalent as a matter of law.

Five phrases draw letters: “FDA-approved” applied to a compounded medication; “generic Zepbound”; “same as” or “identical to” a branded product; trial results quoted for a compounded preparation; and “FDA-registered” presented as though it meant approved.

How to read your own provider against this

A provider's language is evidence about its compliance posture, and it is evidence you can assess without any technical knowledge. A company describing a compounded preparation accurately — not approved, not a generic, not covered by the trials — is telling you it has read the same letters.

The single most useful question remains which pharmacy fills the prescription and under which registration. Not one provider in our dataset has answered it, which is why every pharmacy relationship on this site carries a reported rather than verified label.

What the compounded market actually looked like

At its 2024 peak, compounded GLP-1 preparations reached an estimated 30% of US supply, at roughly $150 to $300 a month against branded list prices above $1,000. That volume is the reason the regulatory question matters commercially rather than academically: a rule change does not adjust a niche, it reorganises a market that several million people rely on.

The economics have shifted underneath the argument in any case. Brand Zepbound is now $299 to $449 direct from LillyDirect. Both approved oral GLP-1s start at $149. Eligible Medicare enrollees pay $50 through the GLP-1 Bridge. Sixteen compounded offerings in our dataset cost more than $299 — which means for a meaningful share of the market, the affordability argument that justified compounding has already inverted without any regulatory action at all.

That matters for how you read provider messaging about this proposal. A company describing compounded medicine as the only affordable route is describing a market that existed eighteen months ago.

Who is actually exposed

Exposure depends entirely on which statutory pathway supplies your prescription, and almost no patient knows which one applies to them. If your medication comes from a 503B outsourcing facility compounding from bulk substances, the proposal targets that route directly. If it comes from a 503A pharmacy compounding for you as an identified patient, the proposal does not address it.

The distinction is not visible from the packaging, the price, or the provider's marketing. It requires asking. And in our dataset, not one provider has named its fulfilling pharmacy or its registration class — which means every patient in this market is exposed to a decision they cannot currently assess.

That is the single most useful thing this proposal has surfaced. Whatever the agency determines, a patient who knows which pathway supplies them can plan; one who does not is waiting to find out.